Sort
48,018 grants matching “immunotherapy”
Targeting Alloreactivity for Leukemia Eradication
$494,554Stanley R Riddell · Fred Hutchinson Cancer Research Center · P01 · FY2007 · CA
Administrative Core
$494,546Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2019 · CA
Administrative Core
$494,546Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2020 · CA
NGF recruits nerve fibers to reprogram an immunosuppressive microenvironment in melanoma
$494,541Xiao-Fan Wang · Duke University · R01 · FY2023 · CA
Tumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLC
$494,498Phuoc T. Tran · University Of Maryland Baltimore · R01 · FY2024 · CA
A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis
$494,488Gary Fanger · Rise Therapeutics, Llc · R44 · FY2023 · AG
Protein Sequencing Tools for Biological Therapeutics
$494,418David Fenyo · Protein Metrics, Llc · R42 · FY2015 · GM
Protein Sequencing Tools for Biological Therapeutics
$494,418David Fenyo · Protein Metrics, Llc · R42 · FY2016 · GM
Controllable In Vivo Genome Editing for Immune-Checkpoint Blockade in Solid Tumors
$494,410Sheng Tong · University Of Kentucky · R01 · FY2021 · EB
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion
$494,409Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2024 · AI
Molecular pathogenesis of Blastomycosis
$494,393Bruce Steven Klein · University Of Wisconsin-Madison · R01 · FY2015 · AI
Molecular pathogenesis of Blastomycosis
$494,393Bruce Steven Klein · University Of Wisconsin-Madison · R01 · FY2019 · AI
Resource for Nonhuman Primate Immune Reagents
$494,370Francois J Villinger · Emory University · R24 · FY2014 · OD
Role of T Cell Immunity in Primate AIDS
$494,307Emory University · R01 · FY2002 · AI
Mechanism of antibody-mediated immunotherapy in AD
$494,300Rockefeller University · R01 · FY2001 · AG
IL-17-driven mechanisms for tumor progression and resistance to therapies
$494,293Thaddeus S Stappenbeck · Cleveland Clinic Lerner Com-Cwru · P01 · FY2024 · CA
Two Compartment Models to Improve Brain Tumor Therapy
$494,277Edward A Neuwelt · Oregon Health & Science University · R01 · FY2008 · CA
Nanoscale Metal-Organic Frameworks Enable Radiotherapy-Radiodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Generate Tumor Vaccines and Potentiate Immunotherapy of Head and Neck Cancers
$494,273Wenbin Lin · University Of Chicago · R01 · FY2022 · CA
Nanoscale Metal-Organic Frameworks Enable Radiotherapy-Radiodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Generate Tumor Vaccines and Potentiate Immunotherapy of Head and Neck Cancers
$494,273Wenbin Lin · University Of Chicago · R01 · FY2023 · CA
Development of SUV39H1-selective inhibitor for human colon cancer therapy
$494,269Kebin Liu · Augusta University · R01 · FY2024 · CA
RADIOPHARMACY AND ASSAYS
$494,263David Morris Colcher · Beckman Research Institute/City Of Hope · P01 · FY2009 · CA
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer
$494,251Michelle S Bradbury · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA
Examining the effects of Global Budget Revenue Program on the Costs and Quality of Care Provided to Cancer Patients Undergoing Chemotherapy
$494,244Anaeze C Offodile · Sloan-Kettering Inst Can Research · R37 · FY2024 · CA
NGF recruits nerve fibers to reprogram an immunosuppressive microenvironment in melanoma
$494,201Xiao-Fan Wang · Duke University · R01 · FY2022 · CA
Alpha particles combined with ATR inhibition to activate the immune system: mechanisms and pre-clinical translation
$494,190Gabriel Oliveira Sawakuchi · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA